Matches in Wikidata for { <http://www.wikidata.org/entity/Q65398348> ?p ?o ?g. }
Showing items 1 to 40 of
40
with 100 items per page.
- Q65398348 description "clinical trial" @default.
- Q65398348 description "ensayu clínicu" @default.
- Q65398348 description "klinisch onderzoek" @default.
- Q65398348 description "клінічне випробування" @default.
- Q65398348 description "կլինիկական փորձարկում" @default.
- Q65398348 name "Guadecitabine and Donor Lymphocyte Infusion in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Relapsing After Allogeneic Stem Cell Transplant" @default.
- Q65398348 name "Guadecitabine and Donor Lymphocyte Infusion in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Relapsing After Allogeneic Stem Cell Transplant" @default.
- Q65398348 type Item @default.
- Q65398348 label "Guadecitabine and Donor Lymphocyte Infusion in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Relapsing After Allogeneic Stem Cell Transplant" @default.
- Q65398348 label "Guadecitabine and Donor Lymphocyte Infusion in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Relapsing After Allogeneic Stem Cell Transplant" @default.
- Q65398348 prefLabel "Guadecitabine and Donor Lymphocyte Infusion in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Relapsing After Allogeneic Stem Cell Transplant" @default.
- Q65398348 prefLabel "Guadecitabine and Donor Lymphocyte Infusion in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Relapsing After Allogeneic Stem Cell Transplant" @default.
- Q65398348 P1050 Q65398348-59B0AF30-FEB3-415D-9C49-79DE64951E38 @default.
- Q65398348 P1050 Q65398348-6B4DC291-518E-4951-AF82-20F9261C537A @default.
- Q65398348 P1050 Q65398348-E481031C-8AA4-4809-B323-6C8F9B904399 @default.
- Q65398348 P1132 Q65398348-0483A67E-8FE1-4105-9E38-571BE676F292 @default.
- Q65398348 P1476 Q65398348-ED7C5F1F-5E72-4D20-98E5-59430FA9D53A @default.
- Q65398348 P17 Q65398348-D42A5878-1BB8-4BDA-B508-39D570566259 @default.
- Q65398348 P2899 Q65398348-81B50FC6-73EA-4A66-8719-222C20913488 @default.
- Q65398348 P3098 Q65398348-2BC5DFC5-BA31-4C75-8D83-8AB58CFEB3FD @default.
- Q65398348 P31 Q65398348-80C84D0F-DBA3-44E3-9871-D76DE7172571 @default.
- Q65398348 P4135 Q65398348-6BD45794-4FEA-4662-8471-443716654AF6 @default.
- Q65398348 P580 Q65398348-A73F429A-60F4-4355-B227-B461658F5C85 @default.
- Q65398348 P582 Q65398348-30F20080-BB5B-45B2-ABBB-5F00C730DFB1 @default.
- Q65398348 P6099 Q65398348-E1F63D73-7498-4E34-A33B-BFA96836961B @default.
- Q65398348 P8363 Q65398348-2247CB27-8BD7-4BA2-942A-4810262BF807 @default.
- Q65398348 P1050 Q179630 @default.
- Q65398348 P1050 Q29496 @default.
- Q65398348 P1050 Q58833980 @default.
- Q65398348 P1132 "+90" @default.
- Q65398348 P1476 "A Phase II Trial to Assess the Efficacy and Toxicity of SGI-110 With DLI for the Treatment of AML or MDS Relapsing After Allogeneic Stem Cell Transplantation" @default.
- Q65398348 P17 Q30 @default.
- Q65398348 P2899 "+18" @default.
- Q65398348 P3098 "NCT02684162" @default.
- Q65398348 P31 Q30612 @default.
- Q65398348 P4135 "+75" @default.
- Q65398348 P580 "2016-06-22T00:00:00Z" @default.
- Q65398348 P582 "2021-06-30T00:00:00Z" @default.
- Q65398348 P6099 Q42824440 @default.
- Q65398348 P8363 Q78089383 @default.